Artificial intelligence in healthcare refers to the use of computer systems that can analyze medical data, recognize patterns, and support clinical decisions in ways that previously required human expertise alone. The field has grown rapidly, with the FDA now listing over 1,430 authorized AI-enabled medical devices, and the global market is projected to reach $50.7 billion in 2026. In practice, AI touches nearly every stage of medicine: screening mammograms, predicting heart failure, tailoring cancer treatments to a patient’s genes, and even helping doctors finish their paperwork faster.
How AI Actually Works in Medicine
AI in healthcare isn’t one technology. It’s a collection of tools, each suited to different jobs. The three most common are machine learning, natural language processing, and computer vision.
Machine learning is the broadest category. These systems learn from large datasets to find patterns that humans might miss. A machine learning model trained on thousands of tumor biopsies, for instance, can learn which cellular features predict whether a cancer will respond to treatment or come back. The models improve as they see more data, which is why healthcare (with its enormous volume of patient records, lab results, and imaging studies) is such a natural fit.
Natural language processing, or NLP, handles the messy, unstructured text that fills medical records. Doctors’ notes, pathology reports, and even recorded conversations between patients and clinicians contain valuable information, but it’s locked in sentences rather than organized in neat spreadsheets. NLP can read through these documents, pull out key terms like diagnoses, medication names, and symptoms, and summarize them. That makes it possible to automate tasks like symptom checking, patient triage, and pulling together a patient’s full history in seconds.
Computer vision powers the AI tools that interpret medical images: X-rays, MRIs, CT scans, and pathology slides. These systems are trained on millions of labeled images so they can flag abnormalities a human eye might overlook, or confirm what a radiologist already suspects.
AI in Diagnostic Imaging
Radiology is where AI has made its most visible impact. More FDA-authorized AI devices focus on medical imaging than any other category, and breast cancer screening is one of the most studied applications.
A recent study comparing AI to radiologists on screening mammograms found nuanced results. Out of 158 biopsies, radiologists detected 64.5% of cancers while AI caught 57%, a gap that wasn’t statistically significant. Radiologists were more sensitive overall (98% vs. 87%), meaning they were better at catching true positives. But AI was more specific (44.4% vs. 17%), meaning it was better at correctly ruling out cancer when it wasn’t there. AI also had a higher positive predictive value (74% vs. 69%), so when it flagged something as suspicious, it was right more often.
The picture shifted depending on breast density. In non-dense breasts, AI’s specificity jumped to 58% compared to 16% for radiologists, and its positive predictive value rose to 82%. In 12 cases where the two disagreed, though, radiologists correctly identified every cancer that AI missed, while AI didn’t catch any errors the radiologists made. The takeaway isn’t that AI is better or worse than a human radiologist. It’s that the two have complementary strengths, and pairing them could reduce both missed cancers and unnecessary biopsies.
Personalized Treatment Through Genomics
One of AI’s most promising roles is in precision medicine, where treatments are tailored to a patient’s genetic makeup rather than applied as a one-size-fits-all protocol. The core idea: your genes influence how you respond to specific drugs, how likely a cancer is to recur, and which therapies carry the best odds of working for you specifically.
The challenge is that genomic data is staggeringly complex. A single patient’s genetic profile, combined with their clinical records, creates a dataset too vast and intricate for any physician to manually parse. AI models, particularly neural networks and classification algorithms, can sift through this information to identify which genetic features matter most. Research has shown that mutations in specific tumor suppressor genes like TP53 and BRCA1 are among the strongest predictors of treatment response and cancer recurrence. AI systems trained on combined genomic and clinical data can flag these mutations and help oncologists choose therapies with the highest likelihood of success for each individual patient.
This approach requires assembling large databases that merge genetic sequencing results with electronic health records and patient-reported outcomes. The models learn which combinations of genetic and clinical features predict relapse, drug resistance, or favorable response, then apply those patterns to new patients.
Predicting Emergencies Before They Happen
AI-powered wearable sensors are changing how patients are monitored after they leave the hospital. A University of Utah study followed 100 heart failure patients (average age 68) across four VA hospitals. After discharge, each patient wore an adhesive sensor patch on their chest 24 hours a day for up to three months. The patch continuously tracked heart rate, heart rhythm, respiratory rate, walking, sleep, and body posture.
That data streamed via Bluetooth to a smartphone and then to an AI analytics platform, which established a personalized baseline for each patient. When readings drifted from that baseline, the system flagged that the patient’s heart failure was worsening. The results were striking: the system accurately predicted the need for rehospitalization more than 80% of the time, with warnings coming an average of 10.4 days before the patient was actually readmitted. The median lead time was 6.5 days. That’s potentially enough time for a care team to intervene, adjust medications, or schedule an urgent visit before a full crisis develops.
Reducing the Paperwork Burden
Physicians in the U.S. spend a significant portion of their day on documentation rather than patient care, and burnout tied to electronic health records is a well-documented problem. AI scribes, tools that listen to patient-clinician conversations and automatically draft visit notes, are one of the most widely adopted AI solutions in clinical settings.
A study from Mass General Brigham published in JAMA found that AI scribes reduced daily electronic health record usage by about 13 minutes and documentation time by 16 minutes, representing relative decreases of 3% and 10%. Clinicians using the tools also saw a slight bump in productivity: about half an additional patient visit per week. Those numbers may sound modest, but clinicians who used AI scribes for more than half their visits experienced twice the reduction in total record-keeping time and three times the reduction in documentation time. The problem is adoption: only 32% of users relied on the technology that frequently.
Bias and Fairness Concerns
AI systems are only as fair as the data they learn from, and healthcare data carries decades of systemic inequity. One widely cited example involved an AI tool used across several U.S. health systems that was designed to identify patients needing extra care management. The algorithm relied on historical cost data as a proxy for health needs. Because Black patients had historically received less healthcare spending (not because they were healthier, but because of barriers to access), the system systematically prioritized healthier white patients over sicker Black patients.
This type of bias can be subtle. Algorithms may predict lower health risks for populations that have historically had less access to care, simply because there’s less documented usage in their records. The absence of data gets misread as the absence of illness.
Addressing this requires several layers of effort. Diversifying training datasets to better reflect the actual demographic makeup of the population is a starting point: increasing representation of minority groups in clinical trials and health records helps train more equitable systems. Regular audits of AI decision-making can catch biases that emerge over time as patient populations or care patterns shift. And involving ethicists, sociologists, and patient advocates in AI development, not just engineers, provides broader perspective on how these tools affect real communities. AI systems need to evolve alongside changing medical understanding and societal norms, with ongoing correction rather than a one-time fix.
The Scale of AI Adoption
The numbers reflect how quickly healthcare is embracing these tools. The global AI in healthcare market was valued at $36.67 billion in 2025 and is expected to grow at a compound annual rate of nearly 39% through 2033, reaching an estimated $505.59 billion. The FDA’s list of authorized AI-enabled medical devices has swelled to over 1,430 as of early 2026, spanning radiology, cardiology, pathology, and dozens of other specialties.
What this growth means for patients is a healthcare system that increasingly uses AI as a layer of support beneath human decision-making. AI reads your chest X-ray before the radiologist does, flags a worrisome trend in your wearable data before you feel symptoms, and drafts your visit notes so your doctor can spend more time talking to you. It doesn’t replace clinical judgment. It handles the data-heavy, pattern-recognition tasks that machines do well, freeing clinicians to focus on the parts of medicine that require human insight, empathy, and nuance.